Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Notable Labs (NTBL – Research Report) with bullish sentiments.
Amgen (AMGN)
Jefferies analyst Michael Yee maintained a Buy rating on Amgen today and set a price target of $375.00. The company’s shares closed last Friday at $267.28.
According to TipRanks.com, Yee is a 1-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $311.72, implying a 16.0% upside from current levels. In a report issued on April 3, RBC Capital also maintained a Buy rating on the stock with a $329.00 price target.
See today’s best-performing stocks on TipRanks >>
Notable Labs (NTBL)
In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Notable Labs, with a price target of $7.00. The company’s shares closed last Friday at $1.16, close to its 52-week low of $1.01.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
Currently, the analyst consensus on Notable Labs is a Moderate Buy with an average price target of $8.00, a 583.8% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- Early notable gainers among liquid option names on April 11th
- Amgen shares worth $240-$250 without obesity pipeline, says JPMorgan
- AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
- Amgen upgraded to Conviction Buy from Buy at Goldman Sachs
- Jefferies biotechnology analyst to hold an analyst/industry conference call
